INTEGRAL BIOSYSTEMS, LLC
Website: Company Website
Address: 23 Crosby Dr Ste 100a, Bedford, Massachusetts, 01730-1423
Phone: (617) 820-8483
Contact Person: DAVE KARASIC
Legal Structure: LLC
Year Established: 2009
Business Type: Research and Development (100 %)
Principals: 1. Shikha P Barman, CEO 2. David P Karasic, COO
Ownership: Other Minority Owned, Self-Certified Small Disadvantaged Business, Subcontinent Asian American, Economically Disadvantaged Women-Owned Small Business, Women-Owned Small Business, Woman Owned
Products & Services
Capabilities Statement Integral BioSystems, LLC is owned and led by a minority woman since its founding in 2009, with expertise in drug R&D, available to assist primary contractors and the NIH (and other appropriate government agencies) by providing the following services: ? Analytical method development ? Analytical method qualification ? Formulation development ? Process Development and Scale up ? ICH Stability Studies ? USP IV Flow-through IVRT studies ? Toxicology clean supplies and cGLP release testing ? Bioanalytical method development ? Scale-up and Technology Transfer ? Ophthalmic, Otic, Dermal and Sublingual Route expertise ? Extensive expertise in sustained release delivery systems ? Extensive subject matter expertise in ophthalmic drug delivery with subject matter expertise with lipid nanoparticles and PLGA microspheres ? Oral films to deliver vaccines DUNS: 786575287; Cage code-6SVP3; NAICS CODE-541714 Will Accept Credit Cards
Keywords
- Pharmaceutical-development
- Sustained-release-formulations
- Ophthalmic-formulations
- Sustained-release-microsphere-formulations
- Injectables
- Bio-analytics
- Hplc
- Ich Stability-testing
- Otc-drugs
- Prescription-drugs
- Lipid-based-nanoparticulate-eyedrops
- Eardrops
- Transdermal Creams & Patches
- Oral Films
- Sustained-release-depots
- Particle Sizing
- Ivrt
- Microscopy
- Dsc
- Sem
- Osmolarity-testing
- Dissolution-testing
- Sustained-release-protein-therapeutics
- Electrospinning-sustained-release-drugs
Contract History
Name: FHI360
Contract: Depot Contraceptive
Start: 06/15/2022
End: 06/15/2023
Value: 250,000
Contact: Available Upon Request
Phone:
Name: ONL Therapeutics
Contract: Ophthalmic Injection
Start: 02/15/2023
End: 07/15/2023
Value: 250,000
Contact: Available Upon Request
Phone:
Name: Aldeyra Therapeutics
Contract: Dry Eye
Start: 05/05/2015
End: 09/15/2018
Value: 350,000
Contact: Available Upon Request
Phone:
Name: Davos Pharmaceuticals
Contract: Anti-cancer Liposome
Start: 06/15/2018
End: 03/30/2024
Value: 450,000
Contact: Available Upon Request
Phone:
Name: Encore Vision
Contract: Presbiopia Drug
Start: 04/05/2015
End: 09/15/2016
Value: 750,000
Contact: Available Upon Request
Phone:
Name: Meibomian Solutions
Contract: Dry Eye
Start: 11/15/2023
End: 04/01/2024
Value: 85,000
Contact: Available Upon Request
Phone:
Name: Generian Pharmaceuticals
Contract: Ocular Injection
Start: 01/25/2023
End: 07/31/2023
Value: 350,000
Contact: Available Upon Request
Phone:
Name: Endogena
Contract: Ocular Injection
Start: 09/06/2019
End: 03/15/2024
Value: 450,000
Contact: Available Upon Request
Phone:
Name: Dompe
Contract: Keratitis Drug
Start: 08/15/2022
End: 09/15/2024
Value: 250,000
Contact: Available Upon Request
Phone:
Name: Perfuse Therapeutics
Contract: Glaucoma Eyedrop
Start: 08/15/2019
End: 05/15/2020
Value: 150,000
Contact: Available Upon Request
Phone:
Name: Nacuity Pharma
Contract: Cystinosis Drug
Start: 05/05/2021
End: 12/15/2023
Value: 550,000
Contact: Available Upon Request
Phone:
Name: Allysta Pharmaceuticals
Contract: Liver Disease
Start: 05/15/2016
End: 02/01/2024
Value: 600,000
Contact: Available Upon Request
Phone:
If you notice any discrepancies in your company profile, or wish to request updates or removals, please contact us to ensure your information is accurate and up-to-date.